BCL2 and cancer: Navitoclax (ABT-263), a BCL-2/BCL-XL family inhibitor originally developed as an anti-cancer drug, selectively eliminates senescent cells dependent on BCL-2 family survival signaling; however its use is limited by tissue toxicity [122].